A study published in Science on July 16, 2026, found that reducing EP2 signaling helped tissue-resident macrophages clear senescent CXCR4-positive neutrophils in aged mice. The research also linked aging to changes in human liver and heart datasets, but those analyses were not clinical treatment results. The study focuses on a specific immune-cell interaction, not the removal of every type of senescent cell.
What reducing EP2 changed in aged mice
Tissue-resident macrophages (TRMs) are long-lived immune cells that live in organs and help maintain tissue health. In aged mice, deleting EP2 specifically in TRMs restored their mitochondrial fitness and immune homeostasis. The researchers also reported that several age-related outcomes moved toward youthful states, including cognitive decline, frailty, sarcopenia, adiposity and cardiac dysfunction.
The study reported a separate result in ex vivo clearance assays: EP2 deletion or pharmacological antagonism restored the removal of senescent neutrophils. These experiments and the aged-mouse outcomes describe preclinical research, not an established treatment for people.
How EP2 disrupts neutrophil clearance
The study identified senescent CXCR4-positive neutrophils as a key target of TRM clearance. Senescent cells have stopped dividing, and these neutrophils accumulated across organs involved in cell clearance in the mouse research.
EP2 is a receptor for prostaglandin E2 (PGE2), a signaling molecule. When EP2 signaling impaired clearance, it weakened the integrin-dependent stabilization that helps a neutrophil remain attached to a TRM. That made the next step, engulfment by the macrophage, less effective. Efferocytosis is the process of engulfing and clearing cells; here, the finding concerns senescent neutrophils rather than senescent cells in general.
What the human tissue data show
Analyses of aged human liver and heart datasets found increased EP2 in TRMs, enrichment of senescent neutrophils and fewer interactions between the two cell types. These are age-associated tissue findings. They do not show that reducing EP2 improves health or treats aging in people.
